newsfilter
← Latest News
GlobeNewswire·

BioStem Technologies Announces Notice of Allowance for Four U.S. Design Patent Applications Covering Fenestrated Human Placental Allografts and One European Patent

  • BioStem Technologies received Notices of Allowance from the USPTO for four new divisional U.S. design patents (No. 30/010,024; 30/010,026; 30/010,032; 30/010,034) related to fenestrated human placental allograft technologies.
  • The European Patent Office issued a new patent (EP4442316A2) covering sterile human placental allografts & proprietary manufacturing methods for growth factor-rich placental tissue allografts.
  • The four U.S. design patents focus on fenestrated designs that improve conformability, fluid transfer, drainage, handling characteristics, & structural integrity of amniotic & chorion tissues.
  • The European patent covers processing methods using gentle cleaning, low-temperature dehydration, & low-dose e-beam sterilization to preserve natural structural integrity & endogenous growth factors.
  • BioStem's total intellectual property portfolio now exceeds 70 patents while advancing next-generation product development for wound care, surgical, dental, & cosmetic applications.
  • CEO Jason Matuszewski stated these milestones protect BioStem's innovations & differentiate the company's offerings to drive clinician adoption.